ELVN
Enliven Therapeutics, Inc.16.91
-0.26-1.51%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.00BP/E (TTM)
-Basic EPS (TTM)
-1.81Dividend Yield
0%Recent Filings
8-K
Positive ELVN-001 Phase 1b CML data
Enliven Therapeutics reported positive initial Phase 1b data for ELVN-001 in heavily pretreated CML patients, with MMR rates of 47% at 80 mg QD (n=19) and 69% at 60/120 mg QD (n=41) by 24 weeks. Phase 3 ENABLE-2 trial initiation is planned for H2 2026, backed by $463 million in cash funding into H1 2029. Leadership strengthened with new CEO. Data fuels pivotal push.
10-K
FY2025 results
Enliven Therapeutics posted FY2025 net loss of $103.7M, up from $89.0M in FY2024, driven by $85.9M R&D (up 6.3% y/y) and $33.8M G&A (up 42.1% y/y), offset by $16.0M other income. Cash reached $462.6M after $230M public offering and $40M ATM sales, funding into H1 2029. ELVN-001 Phase 1 ENABLE trial showed 47% MMR by 24 weeks (n=53) at April cutoff, with Phase 1b 80mg cohort hitting 38% MMR/16% DMR (n=19) by December; randomized cohorts reached 53% MMR/35% DMR (n=26 evaluable). ENABLE-2 Phase 3 to start H2 2026. ELVN-002 deprioritized. Clinical delays from trial failures could stall pipeline momentum.
8-K
Garland joins Enliven board
Enliven Therapeutics appointed Scott Garland, a biopharma commercialization veteran, as Class I director and Nominating Committee Chair effective January 7, 2026, coinciding with Andrew Phillips' resignation amid the shift to late-stage development. Garland, previously a consultant paid $314,650 with options for 26,580 shares, receives $50,000 annual cash and $650,000 in stock options. Board bolsters commercialization expertise. Yet risks shadow Phase 3 plans.
8-K
Enliven names experienced CEO Fair
Enliven Therapeutics appointed Richard Fair as President and CEO, effective December 11, 2025, bringing 25 years of oncology commercialization experience from Roche/Genentech and Bellicum. Founder Samuel Kintz shifts to Head of Pipeline, with 140,457 stock options accelerating. New CEO gets $660,000 salary, 55% target bonus, and options for 875,000 shares. Leadership bolsters Phase 3 CML trial push.
8-K
ENABLE Phase 1b enrollment done
Enliven Therapeutics completed enrollment in the Phase 1b randomized cohorts of its ENABLE trial for ELVN-001 in CML patients, staying on track for a Phase 3 pivotal trial in 2026. Cash hit $478M as of September 30, 2025, funding operations into mid-2029. R&D expenses dropped to $18.2M from $21.3M year-over-year. Strong runway ahead.
IPO
Employees
Sector
Industry
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CLLS
Cellectis S.A.
4.06-0.73
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
ENGN
enGene Holdings Inc.
8.38-0.05
ENLV
Enlivex Therapeutics Ltd.
0.85-0.01
ENVB
Enveric Biosciences, Inc.
5.24-0.12
ENZN
Enzon Pharmaceuticals, Inc.
0.05+0.00
EPIX
ESSA Pharma Inc.
0.20+0.00
LIXT
Lixte Biotechnology Holdings, I
4.10+0.11
TOVX
Theriva Biologics, Inc.
0.21+0.01